Cipla enters into licensing pact with Eli Lilly for Baricitinib drug1 min read 10 May 2021, 09:07 AM IST
The company said it will leverage its distribution footprint to make this therapy accessible to more patients and markets.
Cipla Limited on Monday announced that it has entered into a licensing agreement with Eli Lilly to expand access to Covid-19 treatment in India. The pharma company has signed a royalty-free, non-exclusive voluntary licensing agreement with US' Eli Lilly for the manufacture and commercialization of the drug Baricitinib for Covid-19 indication, it said in a filing.
Select your Category